



OFFICIAL PUBLICATION OF
THE MINISTRY OF HEALTH,
BRUNEI DARUSSALAM

Brunei International Medical Journal

Volume 14

5 August 2018 (24 Zulkeadah 1439H)

INCIDENCE AND CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE IN BRUNEI DARUSSALAM.

Ong HL¹, Idris FI¹, Telisinghe PU², Chong VH^{1, 3}

¹ PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, BE1410, Brunei Darussalam.

² Department of Pathology, and ³ Department of Gastroenterology, Raja Isteri Pengiran Anak Saleha Hospital, Jalan Putera Al Muhtadee Billah, Bandar Seri Begawan, BA1710, Brunei Darussalam.

ABSTRACT

Introduction: The incidence of inflammatory bowel disease (IBD) is increasing worldwide. However, rates are much lower in the developing nations compared to the developed nations. This study assessed the incidence and characteristics of patients with IBD in Brunei Darussalam, a developing Southeast Asian nation with a predominantly Malay population. **Materials and Methods:** A total of 83 patients (41 males and 30 females) were diagnosed with IBD between 2004 and 2016. Clinical case notes were systematically reviewed and demographic data and presenting complaints were collected and analysed. **Results:** The overall number of cases of IBD remained small but incidence rates were increasing (0.28 per 100,000 population in 2004 to 3.08 per 100,000 population in 2016). Ulcerative Colitis (UC) (n=56, 67.5%) was more common than Crohn's Disease (CD) (n=27, 32.5%) and both showed increasing rates over the 13-year period (UC; 0.28/100,000 population in 2004 to 1.66/100,000 population in 2016 and CD; 0/100,000 population in 2004 to 1.42/100,000 population). The overall mean age at diagnosis was 36.0 ± 17.2 years; UC 39.6 ± 17.6 years and CD 28.4 ± 13.9 years. At presentations, UC patients were more likely to present with bleeding per rectum ($p < 0.001$), diarrhoea ($p = 0.003$) and tenesmus ($p = 0.019$) while CD patients were more likely to present with weight loss ($p = 0.008$). In UC, extensive colitis (involvement proximal to splenic flexure) was seen in 32.7% and rectal sparing in 12.2%. In CD, 52.6% had ceacal involvements. **Conclusions:** Our study showed that IBD is increasing in Brunei Darussalam, more in UC than CD. The characteristics of our patients are similar to what have been reported. Age of diagnosis was older in UC than CD and although there are overlap, certain clinical presentations were common to each condition.

Keywords: Inflammatory bowel disease, Incidence, Crohn's disease, Ulcerative colitis

Brunei Int Med J. 2018;14:120-127

Brunei International Medical Journal (BIMJ) Official Publication of the Ministry of Health, Brunei Darussalam

EDITORIAL BOARD

Editor-in-Chief	William Chee Fui CHONG
Sub-Editors	Vui Heng CHONG Ketan PANDE
Editorial Board Members	Nazar LUQMAN Muhd Syafiq ABDULLAH Alice Moi Ling YONG Ahmad Yazid ABDUL WAHAB Jackson Chee Seng TAN Dipo OLABUMUYI Pemasiri Upali TELISINGHE Roselina YAAKUB Pengiran Khairol Asmee PENGIRAN SABTU Dayangku Siti Nur Ashikin PENGIRAN TENGAH

INTERNATIONAL EDITORIAL BOARD MEMBERS

Lawrence HO Khek Yu (Singapore)	Surinderpal S BIRRING (United Kingdom)
Emily Felicia Jan Ee SHEN (Singapore)	Leslie GOH (United Kingdom)
John YAP (United Kingdom)	Chuen Neng LEE (Singapore)
Christopher HAYWARD (Australia)	Jimmy SO (Singapore)
Jose F LAPENA (Philippines)	Simon Peter FROSTICK (United Kingdom)

Advisor

Wilfred PEH (Singapore)

Past Editors

Nagamuttu RAVINDRANATHAN
Kenneth Yuh Yen KOK

Proof reader

John WOLSTENHOLME (CfBT Brunei Darussalam)

Aim and Scope of Brunei International Medical Journal

The Brunei International Medical Journal (BIMJ) is a six monthly peer reviewed official publication of the Ministry of Health under the auspices of the Clinical Research Unit, Ministry of Health, Brunei Darussalam.

The BIMJ publishes articles ranging from original research papers, review articles, medical practice papers, special reports, audits, case reports, images of interest, education and technical/innovation papers, editorials, commentaries and letters to the Editor. Topics of interest include all subjects that relate to clinical practice and research in all branches of medicine, basic and clinical including topics related to allied health care fields. The BIMJ welcomes manuscripts from contributors, but usually solicits reviews articles and special reports. Proposals for review papers can be sent to the Managing Editor directly. Please refer to the contact information of the Editorial Office.

Instruction to authors

Manuscript submissions

All manuscripts should be sent to the Managing Editor, BIMJ, Ministry of Health, Brunei Darussalam; e-mail: editor-in-chief@bimjonline.com. Subsequent correspondence between the BIMJ and authors will, as far as possible via should be conducted via email quoting the reference number.

Conditions

Submission of an article for consideration for publication implies the transfer of the copyright from the authors to the BIMJ upon acceptance. The final decision of acceptance rests with the Editor-in-Chief. All accepted papers become the permanent property of the BIMJ and may not be published elsewhere without written permission from the BIMJ.

Ethics

Ethical considerations will be taken into account in the assessment of papers that have experimental investigations of human or animal subjects. Authors should state clearly in the Materials and Methods section of the manuscript that institutional review board has approved the project. Those investigators without such review boards should ensure that the principles outlined in the Declaration of Helsinki have been followed.

Manuscript categories

Original articles

These include controlled trials, interventional studies, studies of screening and diagnostic tests, outcome studies, cost-effectiveness analyses, and large-scale epidemiological studies. Manuscript should include the following; introduction, materials and methods, results and conclusion. The objective should be stated clearly in the introduction. The text should not exceed 2500 words and references not more than 30.

Review articles

These are, in general, invited papers, but unsolicited reviews, if of good quality, may be considered. Reviews are systematic critical assessments of

literature and data sources pertaining to clinical topics, emphasising factors such as cause, diagnosis, prognosis, therapy, or prevention. Reviews should be made relevant to our local setting and preferably supported by local data. The text should not exceed 3000 words and references not more than 40.

Special Reports

This section usually consist of invited reports that have significant impact on healthcare practice and usually cover disease outbreaks, management guidelines or policy statement paper.

Audits

Audits of relevant topics generally follow the same format as original article and the text should not exceed 1,500 words and references not more than 20.

Case reports

Case reports should highlight interesting rare cases or provide good learning points. The text should not exceed 1000 words; the number of tables, figures, or both should not be more than two, and references should not be more than 15.

Education section

This section includes papers (i.e. how to interpret ECG or chest radiography) with particular aim of broadening knowledge or serve as revision materials. Papers will usually be invited but well written paper on relevant topics may be accepted. The text should not exceed 1500 words and should include not more than 15 figures illustration and references should not be more than 15.

Images of interest

These are papers presenting unique clinical encounters that are illustrated by photographs, radiographs, or other figures. Image of interest should include a brief description of the case and discussion with educational aspects. Alternatively, a mini quiz can be presented and answers will be posted in a different section of the publication. A maximum of

three relevant references should be included. Only images of high quality (at least 300dpi) will be acceptable.

Technical innovations

This section include papers looking at novel or new techniques that have been developed or introduced to the local setting. The text should not exceed 1000 words and should include not more than 10 figures illustration and references should not be more than 10.

Letters to the Editor

Letters discussing a recent article published in the BIMJ are welcome and should be sent to the Editorial Office by e-mail. The text should not exceed 250 words; have no more than one figure or table, and five references.

Criteria for manuscripts

Manuscripts submitted to the BIMJ should meet the following criteria: the content is original; the writing is clear; the study methods are appropriate; the data are valid; the conclusions are reasonable and supported by the data; the information is important; and the topic has general medical interest. Manuscripts will be accepted only if both their contents and style meet the standards required by the BIMJ.

Authorship information

Designate one corresponding author and provide a complete address, telephone and fax numbers, and e-mail address. The number of authors of each paper should not be more than twelve; a greater number requires justification. Authors may add a publishable footnote explaining order of authorship.

Group authorship

If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship described in the following paragraphs. One or more authors may take responsibility 'for' a group, in which case the other group members are not authors, but may be listed in an acknowledgement.

Authorship requirement

When the BIMJ accepts a paper for publication, authors will be asked to sign statements on (1) financial disclosure, (2) conflict of interest and (3) copyright transfer. The correspondence author may sign on behalf of co-authors.

Authorship criteria and responsibility

All authors must meet the following criteria: to have participated sufficiently in the work to take public responsibility for the content; to have made substantial contributions to the conception and de-

sign, and the analysis and interpretation of the data (where applicable); to have made substantial contributions to the writing or revision of the manuscript; and to have reviewed the final version of the submitted manuscript and approved it for publication. Authors will be asked to certify that their contribution represents valid work and that neither the manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, except as described in an attachment. If requested, authors shall provide the data on which the manuscript is based for examination by the editors or their assignees.

Financial disclosure or conflict of interest

Any affiliation with or involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in the manuscript should be disclosed in an attachment. Any financial or material support should be identified in the manuscript.

Copyright transfer

In consideration of the action of the BIMJ in reviewing and editing a submission, the author/s will transfer, assign, or otherwise convey all copyright ownership to the Clinical Research Unit, RIPAS Hospital, Ministry of Health in the event that such work is published by the BIMJ.

Acknowledgements

Only persons who have made substantial contributions but who do not fulfill the authorship criteria should be acknowledged.

Accepted manuscripts

Authors will be informed of acceptances and accepted manuscripts will be sent for copyediting. During copyediting, there may be some changes made to accommodate the style of journal format. Attempts will be made to ensure that the overall meaning of the texts are not altered. Authors will be informed by email of the estimated time of publication. Authors may be requested to provide raw data, especially those presented in graph such as bar charts or figures so that presentations can be constructed following the format and style of the journal. Proofs will be sent to authors to check for any mistakes made during copyediting. Authors are usually given 72 hours to return the proof. No response will be taken as no further corrections required. Corrections should be kept to a minimum. Otherwise, it may cause delay in publication.

Offprint

Contributors will not be given any offprint of their published articles. Contributors can obtain an electronic reprint from the journal website.

DISCLAIMER

All articles published, including editorials and letters, represent the opinion of the contributors and do not reflect the official view or policy of the Clinical Research Unit, the Ministry of Health or the institutions with which the contributors are affiliated to unless this is clearly stated. The appearance of advertisement does not necessarily constitute endorsement by the Clinical Research Unit or Ministry of Health, Brunei Darussalam. Furthermore, the publisher cannot accept responsibility for the correctness or accuracy of the advertisers' text and/or claim or any opinion expressed.

INCIDENCE AND CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE IN BRUNEI DARUSSALAM.

Ong HL¹, Idris FI¹, Telisinghe PU², Chong VH^{1, 3}

¹ PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, BE1410, Brunei Darussalam.

² Department of Pathology, and ³ Department of Gastroenterology, Raja Isteri Pengiran Anak Saleha Hospital, Jalan Putera Al Muhtadee Billah, Bandar Seri Begawan, BA1710, Brunei Darussalam.

ABSTRACT

Introduction: The incidence of inflammatory bowel disease (IBD) is increasing worldwide. However, rates are much lower in the developing nations compared to the developed nations. This study assessed the incidence and characteristics of patients with IBD in Brunei Darussalam, a developing Southeast Asian nation with a predominantly Malay population. **Materials and Methods:** A total of 83 patients (41 males and 30 females) were diagnosed with IBD between 2004 and 2016. Clinical case notes were systematically reviewed and demographic data and presenting complaints were collected and analysed. **Results:** The overall number of cases of IBD remained small but incidence rates were increasing (0.28 per 100,000 population in 2004 to 3.08 per 100,000 population in 2016). Ulcerative Colitis (UC) (n=56, 67.5%) was more common than Crohns Disease (CD) (n=27, 32.5%) and both showed increasing rates over the 13-year period (UC; 0.28/100,000 population in 2004 to 1.66/100,000 population in 2016 and CD; 0/100,000 population in 2004 to 1.42/100,000 population). The overall mean age at diagnosis was 36.0 ± 17.2 years; UC 39.6 ± 17.6 years and CD 28.4 ± 13.9 years. At presentations, UC patients were more likely to present with bleeding per rectum ($p < 0.001$), diarrhoea ($p = 0.003$) and tenesmus ($p = 0.019$) while CD patients were more likely to present with weight loss ($p = 0.008$). In UC, extensive colitis (involvement proximal to splenic flexure) was seen in 32.7% and rectal sparing in 12.2%. In CD, 52.6% had ceecal involvements. **Conclusions:** Our study showed that IBD is increasing in Brunei Darussalam, more in UC than CD. The characteristics of our patients are similar to what have been reported. Age of diagnosis was older in UC than CD and although there are overlap, certain clinical presentations were common to each condition.

Keywords: Inflammatory bowel disease, Incidence, Crohn's disease, Ulcerative colitis

INTRODUCTION

The global incidence of inflammatory bowel disease (IBD) which consist mainly of Ulcerative Colitis (UC) and Crohns Disease (CD) is increasing and its emergence in Asian coun-

tries has been attributed to the modernisation with change in diet and lifestyle.¹ In developed nations, such as Europe and North America, the reported annual incidence rates of IBD have been between 20.2 and 24.3 per 100,000 population.² While it is less common in Asia, there have been reports of increasing incidence rates. East Asian countries, such as South Korea, Japan and China have reported incidence rates ranging between 0.54 and

Correspondence: Hui Ling ONG, PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, BE1410, Brunei Darussalam.

Telephone: +673 8635142

Email: huilong.ong@outlook.com

3.44 per 100,000 population. Singapore and Malaysia, two neighbouring nations to Brunei Darussalam have reported lower incidence rates of 1.06 and 0.94 per 100,000 population, respectively.³ These reflect that IBD are still uncommon in the Southeast Asian region compared to developed nations.

It is well established across Western countries that IBD is more prevalent in Caucasian and Ashkenazi Jewish.⁴ In Asia where there are multi-ethnic populations, certain ethnic groups are more affected. In Southeast nations such as Singapore and Malaysia with multi ethnic populations, Indians have higher incidence.¹ Western and Asian studies have contradicting results when comparing between genders. Western studies found an overall predominance of IBD in females while Asian studies reported predominance in males.⁴ Western studies reported that females had 20-30% higher risk of suffering from CD⁵ but Asian studies stated males were at a higher risk.⁴ However, both Western and Asian studies have not found a gender predominance in the occurrence of UC.⁵ As for the mean age at diagnosis, Western studies reported a peak age of onset at 20-30 years for CD and 30-40 years for UC.³ Patients in Asia were found to be slightly older, with peak age of diagnosis at around 20-39 years for CD and 35-44 for UC.⁶

Clinical studies reported that 95% of UC patients mainly present with bloody stools, and some complain of tenesmus and abdominal pain.⁷ CD can present similarly to UC but its main presenting complaints are chronic diarrhoea, abdominal pain and weight loss. UC and CD patients can also present with fever, but it is noted to occur more frequently in CD patients.⁸ Terminal ileum and the proximal colon are the most affected segments of the gastrointestinal tract in CD patients. UC is usually confined to the rectosigmoid area and in 20-30% of UC patients the disease extends beyond the hepatic flexure.⁵

At present, there is no published data on IBD in Brunei Darussalam. Due to increasing global incidence rates of IBD, it is important to publish baseline incidence rates of IBD and its presenting characteristics within the Bruneian population for future trend comparison. Thus the aim of this study is to assess the incidence and characteristics of IBD in Brunei Darussalam, a developing Southeast Asian nation with a predominant Malay population.

MATERIALS AND METHODS

The study is a retrospective cross-sectional chart review of patients with confirmed histological diagnosis of IBD, identified from the Disease Registry maintained by the Department of Pathology, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital. Ethic approval was obtained from the Medical Health Research Ethic Committee, Ministry of Health.

Patient Population

Patients diagnosed with UC and CD between 2000 and 2017 were identified through the pathology registry maintained by the Department of Pathology, RIPAS Hospital. Information available from this registry include demographic detail and date of diagnosis. Diagnoses of IBD were based on established criteria of clinical presentations, endoscopic changes, laboratory and characteristic histological features. The histological features used to differentiate between UC and CD were in accordance with the 9th edition of Rosai and Akerman's Surgical Pathology.⁹ Histopathological features of UC included crypt architectural distortion, mononuclear cell infiltration of the lamina propria, mucin depletion and diffuse basal plasmacytosis. While for CD granulomatous inflammation, polynuclear leucocyte infiltration of the lamina propria and presence of epithelioid granuloma and basal giant cells were observed.⁹ Patients who attended consultations at Jerudong Park Medical Centre (JPMC) were excluded as details of their

presentation and management could not be accessed.

Data Collection

Once the patients were identified, the Brunei Health Information Management system (Bru-HIMS) database which was started in 2013 was used to access clinical notes. Clinical data at the time of diagnosis such as age, race, gender, presenting symptoms and extend of disease were collected from the database. For patients diagnosed before implementation of Bru-HIMs, prospectively collected data on patient diagnosed with IBD held by the Division of Gastroenterology and Hepatology was also retrospectively reviewed. This database contains all demographic and clinical information (type of IBD, date of diagnosis, age of diagnosis, clinical presentations and disease extend and severity).

The data was collected using performa that was designed for this study and transposed to Microsoft Excel for analysis.

Statistical analysis

Statistical analysis was done through Statisti-

cal Package for Social Sciences (SPSS), version 23.0. The population census used to calculate the incidences were retrieved from the public website of the Ministry of Health, Brunei Darussalam.¹⁰ Where possible, categorical variables were analysed using Pearson’s Chi-Square. However, when the assumptions for Pearson’s Chi-Square were not met, Fisher’s exact test was used instead. *P* values less than 0.05 ($p < 0.05$) were considered as significant and all *p* values were corrected to 2 decimal places.

RESULTS

The incidence of IBD was found to be generally increasing between 2004 and 2016, rising from 0.28 per 100,000 to 3.08 per 100,000 population (Figure 1). Rising trends were also seen in UC (Figure 2) and CD (Figure 3). The increase was more pronounced for UC compared to CD.

Overall, IBD was more common among males, 49 (59.0%), compared to females, 34 (41.0%). Ethnic breakdown of the patients diagnosed with IBD was consistent




Figure 1: Line graph of Incidence of Inflammatory Bowel Disease (2004 – 2016) with trend line by year.




Figure 2: Line graph of Incidence of Ulcerative Colitis (2004 – 2016) with trend line by year.




Figure 3: Line graph of Incidence of Crohns Disease (2004 – 2016) with trend line by year.

Figure 3: Line graph of Incidence of Crohn’s Disease (2004 – 2016) with trend line by year.

Variable	Mean (SD)	n (%)
Age (year)	36.0 (17.2)	
Gender (n=83)		
Malay		50 (60.2)
Chinese		16 (19.3)
Others		17 (20.5)
Diagnosis (n=83)		
CD		27 (32.5)
UC		56 (67.5)
Family History of IBD (n=83)		
		2 (2.4)

SD : Standard Deviation; CD : Crohns disease;
UC : Ulcerative colitis

with the national breakdown. The mean age of diagnosis for IBD was 36.0 ± 17.2, (range: 3 to 83 years) There were more cases of UC seen (67.5%) than CD (32.5%). UC was twice more common than CD (Table 1).

Comparisons between CD and UC showed significant differences in mean age at diagnosis and presenting complaints. The mean age at diagnosis of CD (32.1 ± 13.6) was younger than UC (40.5 ± 17.5), ($p=0.010$). CD patients were less likely to complain of bleeding per rectum/bloody diarrhoea ($p<0.001$) and diarrhoea ($p=0.003$) compared to UC patients. Details are summarised in Tables 1 and 2.

DISCUSSION

In Asia, the incidence of IBD is increasing but the incidence rates remain lower than in European countries and North America.³ Our study found that in Brunei Darussalam, there is also an increasing incidence of IBD with the annual rate ranging from 0.28 to 3.08 per 100,000 population between 2004 and 2016. While the annual incidence rates are lower than our European counterparts, our highest incidence rate has surpassed annual rates of some of our neighbouring countries, such as Singapore (1.06 per 100,000 population) and

Malaysia (0.94 per 100,000 population).³

The trends showed both UC and CD to be increasing, more for UC than CD. The UC trend showed a sharper increase in the number of cases and generally higher number of annual incidence rates when compared to the CD trend. There were wide fluctuations in the trends and this was due to the overall small number of cases, reflecting the size of the population. However, the total number of cases can be considered an accurate representation of the whole country as it included all histology proven cases that presented to healthcare services. In Brunei Darussalam, there is only one central pathology department that processes all tissue samples, hence capturing all histology proven cases.

In previous studies, the incidence of IBD was found to differ significantly between different ethnic groups and genders. In our study, the ethnic groups were broken down into Malay (60.2%), Chinese (19.3%) and others (20.5%). This ratio of roughly 3:1:1 generally resembled the ethnic breakdown of the population of Brunei Darussalam suggesting IBD affects each ethnic group equally. On the other hand, Malaysia, a country with almost similar population ethnicity breakdown, demonstrates a higher incidence rate in Indians, followed by the Chinese and the Malays.³ Our study population included a small number of Caucasian and Indian expatriate populations. Most of the Indian population works in the industrial sector and hence, when diagnosed with chronic diseases requiring long-term treatment, tend to return to their homeland.

When comparing the incidence of CD and UC between males and females, Western studies have reported that females had higher risk of developing CD⁵ while Asian studies have reported males had higher risk.⁴ In both Western and Asian studies, there were no gender predominance found in UC patients.⁵

Table 2: Comparison of demographic data and characteristics between CD and UC.

Variable	CD n (%)	UC n (%)	χ^2 statistics (df)	p value
Mean age (year)	28.4 ± 13.9	39.6 ± 17.6		0.005 ^a
Gender (CD=27;UC=56)				
Male	19 (70.4)	30 (53.6)	2.13 (1)	0.145 ^b
Female	8 (29.6)	26 (46.4)		
Ethnicity (CD=27;UC=56)				
Malay	15 (55.6)	35 (62.5)	2.19 (1)	0.334 ^b
Chinese	4 (14.8)	12 (21.4)		
Others	8 (29.6)	9 (16.1)		
Presenting Complaints (CD=27;UC=52)				
BPR/Bloody Diarrhoea	4 (14.8)	40 (76.9)	27.78 (1)	0.000 ^b
Diarrhoea	11 (40.7)	38 (73.1)	7.89 (1)	0.005 ^b
Abdominal Pain	13 (48.1)	28 (53.8)	0.23 (1)	0.631 ^b
Fatigue	1 (3.7)	7 (13.5)		0.253 ^c
Fever	2 (7.4)	9 (17.3)		0.315 ^c
Weight Loss	9 (33.3)	4 (7.7)		0.008 ^c
Loss of Appetite	2 (7.4)	12 (23.1)		0.122 ^c
Tenesmus	2 (7.4)	16 (30.8)	5.51 (1)	0.019 ^b

df : degree of freedom; CD : Crohns disease; UC : Ulcerative colitis; ^aIndependent *t* test; ^bPearson's Chi-square test; ^cFisher's exact test

Our data supports Asian studies, whereby males are more likely to be affected by CD but there seems to be no gender predilection for UC. While the overall incidence is higher in males than females, when comparing the proportions of males and females suffering from CD or UC, it was found that males and females have an equal risk of developing either disease ($p=0.145$). However, this result may be due to the overall small number of patients affected. Longer term study with more patient studied may provide better understanding.

The mean age at diagnosis for IBD was found to be 36.0 ± 17.2 years old. Additionally, it was found that the age at diagnosis for CD (28.4 ± 13.6 years) is significantly lower than the age of diagnosis for UC (39.6 ± 17.6 years), ($p=0.005$). This is similar to numerous studies which report the age of CD occurrence is younger than the age of UC oc-

currence is younger than the age of UC occurrence.³ However, both means are slightly higher than the reported range in in the United Kingdom, where the median age of diagnosis for CD and UC is 30 and 39 years old respectively.¹¹ On the other hand, Asian studies report a younger median age at diagnosis. In Japan, the median age at diagnosis was reported to be 22 years old for CD¹² while in China, it was reported to be 25 years for UC.¹³ Perhaps, the late presentation in age in this country could partly be due to exclusion of a differential diagnosis of IBD by clinicians or patients' not recognising the significance of their symptoms. A small proportion of mild disease may escape detection if patients have mild forms of the disease and do not proceed to undergo colonoscopy whereas most moderate to severe cases will eventually be diagnosed by colonoscopy and biopsy.

The symptoms recorded in this study

were typical signs of chronic gastrointestinal tract inflammation. Depending on the affected sites, chronic inflammation can lead to ulcerations and loss of mucosal function, resulting in pain, presence of blood in stools and malabsorption of nutrients. Out of the 27 CD patients, 14.8% experienced rectal bleeding or bloody diarrhoea while 76.9% of 52 UC patients experienced it. Similarly, 40.7% of CD and 73.1% of UC patients experience diarrhoea and 7.4% of CD and 30.8% of UC presents with tenesmus. Thus, is a significantly larger proportion of UC patients experiencing rectal bleeding/bloody diarrhoea ($p < 0.001$), diarrhoea ($p = 0.005$) and tenesmus ($p = 0.019$), which is consistent with most literature.^{7, 14} CD patients reported a higher likelihood of experiencing weight loss compared to UC patients ($p = 0.008$). Other common symptoms such as abdominal pain ($p = 0.631$), fatigue ($p = 0.253$), fever ($p = 0.315$) and loss of appetite ($p = 0.122$) were present in both CD and UC patients but there was no significant difference in the proportions between the two groups.

Most studies show that approximately 30-50% of UC patients are affected in rectosigmoid area while in CD, the terminal ileum is the area most affected.⁵ The findings of this study was similar – out of 19 CD patients, 36.8% were affected at the terminal ileum, 52.6% at the caecum, 36.8% at the rectum while out of 49 UC patients, the corresponding percentages of areas affected were 14.3%, 26.5% and 87.8% respectively. This finding can be related to common UC complaints identified in this study. As the rectum is more likely to be involved, rectal manifestations, such as rectal bleeding and tenesmus, would be more common in UC patients rather than CD patients. Unlike most studies, however, our study detected 12.2% of 49 UC patients with rectal sparing, greatly contrasting the reported 0% of absolute rectal sparing in an American study. Initially, the study suggested the experience of 31% prev-

alence rate of relative rectal sparing but upon histological analysis, most of the 31% had architectural distortion in the rectal mucosa.⁹ Similarly, in our 11.9% of UC patients, there may be slight rectal involvement, which perhaps was not biopsied to be confirmed histologically. Hence, the actual percentage of UC patients with absolute rectal sparing cannot be concluded. Moreover, upper gastrointestinal involvements appear to be uncommon for CD patients based on symptoms are presentation. However, this observation may be inaccurate as systematic evaluations, such as upper GI endoscopy or imaging, are not routinely carried out in the absence of symptoms in our setting. Therefore, data regarding the oesophagus, stomach and small intestine cannot be provided. To date, there has been one CD patient with nodular mucosal manifestations in the stomach which resolved with treatment.

It is note-worthy that various studies have been made regarding family history and the occurrence of IBD. Overall, positive family history for IBD is reported in 5–16% of CD patients and 8–14% of UC patients.¹⁵ Mutations at disease-predisposing loci on chromosome 16q, which can be inherited, can result in loss of intestinal mucosal function, leading to a higher risk of developing IBD.¹⁶ Our study only identified two UC patients with a positive family history, neither of whom represented the local population. An explanation could be that IBD is still at its early stages of emergence in Brunei Darussalam, and so a pattern of family history of IBD would not yet be established nor recognised within the population.

CONCLUSION

This study shows that the incidence of IBD is increasing in Brunei Darussalam. Patients with UC were older than CD patient at diagnosis consistent with what have been reported in the literature. However, we did not find any gender and ethnic propensity. The significance

and novelty of this study is that being the only available data on the incidence and characteristics of IBD in Brunei Darussalam, it can serve as a baseline reference for future studies on IBD.

DISCLOSURE

All authors have contributed to the manuscript equally. None of the authors have direct or financial conflicts of interest with this paper and material contained herein.

REFERENCES:

- 1: Siew C. Ng. Inflammatory Bowel Disease in Asia. *Gastroenterol Hepatology.* 2013;9(1):28-30. [accessed 02 August 2016]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975975/>
- 2: Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. *Clin Epidemiol.* 2013;5:237-47. [Accessed 02 August 2016]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728155/>
- 3: Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. *Int Research.* 2016;14(2):111-9. [Accessed 15 February 2017]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863044/>
- 4: M'Koma AE. Inflammatory bowel disease: an expanding global health problem. *Clin Med Insights Gastroenterol.* 2013;6:33-47. [Accessed 20 February 2017]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020403/>
- 5: Langholz E. Current trends in inflammatory bowel disease: the natural history. *Therap Adv Gastroenterol.* 2010;3(2):77-86. [Accessed 05 March 2017]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002570/>
- 6: Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. *World J Gastroenterol: WJG.* 2014;20(33):11525-11537. [Accessed 05 March 2017] Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155345/>
- 7: Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohn's colitis.* 2012;6(10):991-1030. [Accessed 12 August 2016]. Available from: <https://www.sciencedirect.com/science/article/pii/S1873994612004035?via%3DIihub>
- 8: Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. *World J Gastroenterol.* 2015;21(1):21-46. [05 February 2017]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284336/>
- 9: Rosai J. *Gastrointestinal tract.* In: Rosai and Ackermans Surgical Pathology, 9th Edition. Elsevier; 2009. p.785.
- 9: Ministry of Health, Brunei Darussalam. Health Information Booklet 2004-2016. [Accessed 15 March 2018]. Available online: <http://www.moh.gov.bn/SitePages/Health%20Information%20Booklet.aspx>.
- 10: Bardhan KD, Simmonds N, Royston C, Dhar A, Edwards CM. A United Kingdom inflammatory bowel disease database: Making the effort worthwhile. *J Crohn's Colitis.* 2010;4(4):405-12. [Accessed on 2 September 2018]. Available from: <https://academic.oup.com/ecco-jcc/article/4/4/405/490120>
- 11: Oriuchi T, Hiwatashi N, Kinouchi Y, Takahashi S, Takagi S, Negoro K, Shimosegawa T. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. *K Gastroenterol.* 2003;28:942-953.
- 12: Ye L, Cao Q, Cheng J. Review of Inflammatory Bowel Disease in China. *The Scientific World Journal.* 2013;2013:6. [Accessed on 2 September 2018]. Pdf available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848381/pdf/TSWJ2013-296470.pdf>
- 13: Zhou Y, Huang Y. Inflammatory bowel disease in Chinese children: A retrospective analysis of 49 cases. *Exp Therap Med* 12.5 (2016): 3363-3368. [Accessed on 2 September 2018]. Pdf available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103794/pdf/etm-12-05-3363.pdf>
- 14: Stittrich AB, Ashworth J, Shi M, Robinson Max, Mauldin D, Brunkow ME, Biswas S, Kim JM, Kwon, KS, Jung JU, Galas D, Serikawa K, Duerr RH, Guthery SL, Peschon J, Hood L, Roach JC, Glusman G. Genomic architecture of inflammatory bowel disease in five families with multiple affected individuals. *Hum Genome Var* 3. 2016;3:15060. [Accessed on 2 September 2018]. Pdf available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785573/pdf/hqv201560.pdf>
- 15: Mohan H. *The Gastrointestinal tract.* In: Textbook of Pathology, 6th Edition. Jaypee Brothers; 2010. p.565